About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 370426, 9 pages
http://dx.doi.org/10.1155/2012/370426
Review Article

Familial Atypical Hemolytic Uremic Syndrome: A Review of Its Genetic and Clinical Aspects

1Interdepartmental PhD Program in Genetics, University of Iowa, Iowa City, IA52242, USA
2Division of Nephrology, Department of Internal Medicine, Carver College of Medicine, University of Iowa, 5270 CBRB, Iowa City, IA 52242, USA
3Laboratory of Molecular Genetics, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan 20122, Italy
4Center for HUS Control, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan 20122, Italy

Received 6 July 2012; Accepted 24 September 2012

Academic Editor: Michael A. Flierl

Copyright © 2012 Fengxiao Bu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Noris and G. Remuzzi, “Atypical hemolytic-uremic syndrome,” The New England Journal of Medicine, vol. 361, no. 17, pp. 1675–1687, 2009. View at Scopus
  2. A. R. Constantinescu, M. Bitzan, L. S. Weiss et al., “Non-enteropathic hemolytic uremic syndrome: causes and short-term course,” American Journal of Kidney Diseases, vol. 43, no. 6, pp. 976–982, 2004. View at Scopus
  3. M. Noris, J. Caprioli, E. Bresin et al., “Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 10, pp. 1844–1859, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. A. L. Sellier-Leclerc, V. Frémeaux-Bacchi, M. A. Dragon-Durey et al., “Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome,” Journal of the American Society of Nephrology, vol. 18, no. 8, pp. 2392–2400, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Noris, G. Remuzzi, et al., “Atypical hemolytic-uremic syndrome,” in GeneReviews, R. A. Pagon, T. D. Bird, C. R. Dolan, et al., Eds., Seattle, Wash, USA, 1993.
  6. M. A. Dragon-Durey, S. K. Sethi, A. Bagga et al., “Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome,” Journal of the American Society of Nephrology, vol. 21, no. 12, pp. 2180–2187, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Caprioli, M. Noris, S. Brioschi et al., “Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome,” Blood, vol. 108, no. 4, pp. 1267–1279, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. S. R. de Córdoba, “AHUS: a disorder with many risk factors,” Blood, vol. 115, no. 2, pp. 158–160, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. J. H. Brown, J. Tellez, V. Wilson, et al., “Postpartum aHUS secondary to a genetic abnormality in factor H acquired through liver transplantation,” American Journal of Transplantation, vol. 12, no. 6, pp. 1632–1636, 2012.
  10. P. F. Zipfel and C. Skerka, “Complement regulators and inhibitory proteins,” Nature Reviews Immunology, vol. 9, no. 10, pp. 729–740, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. W. Dodds, “Which came first, the lectin/classical pathway or the alternative pathway of complement?” Immunobiology, vol. 205, no. 4-5, pp. 340–354, 2002. View at Scopus
  12. R. R. Porter and K. B. M. Reid, “Activation of the complement system by antibody-antigen complexes: the classical pathway,” Advances in Protein Chemistry, vol. 33, pp. 1–71, 1979. View at Publisher · View at Google Scholar · View at Scopus
  13. M. W. Turner, “The lectin pathway of complement activation,” Research in Immunology, vol. 147, no. 2, pp. 110–115, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Matsushita, “The lectin pathway of the complement system,” Microbiology and Immunology, vol. 40, no. 12, pp. 887–893, 1996. View at Scopus
  15. V. M. Holers, “The spectrum of complement alternative pathway-mediated diseases,” Immunological Reviews, vol. 223, no. 1, pp. 300–316, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. M. K. Pangburn and H. J. Muller-Eberhard, “The alternative pathway of complement,” Springer Seminars in Immunopathology, vol. 7, no. 2-3, pp. 163–192, 1984. View at Scopus
  17. M. K. Liszewski, C. J. Fang, and J. P. Atkinson, “Inhibiting complement activation on cells at the step of C3 cleavage,” Vaccine, vol. 26, supplement 8, pp. I22–I27, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. B. J. C. Janssen and P. Gros, “Conformational complexity of complement component C3,” Advances in Experimental Medicine and Biology, vol. 586, pp. 291–312, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. S. J. Perkins, R. Nan, A. I. Okemefuna, K. Li, S. Khan, and A. Miller, “Multiple interactions of complement factor h with its ligands in solution: a progress report,” Advances in Experimental Medicine and Biology, vol. 703, pp. 25–47, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Skerka and P. F. Zipfel, “Complement factor H related proteins in immune diseases,” Vaccine, vol. 26, supplement 8, pp. I9–I14, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. M. K. Pangburn and N. Rawal, “Structure and function of complement C5 convertase enzymes,” Biochemical Society Transactions, vol. 30, no. 6, pp. 1006–1010, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. B. P. Morgan, “Regulation of the complement membrane attack pathway,” Critical Reviews in Immunology, vol. 19, no. 3, pp. 173–198, 1999. View at Scopus
  23. H. J. Muller-Eberhard, “The membrane attack complex of complement,” Annual Review of Immunology, vol. 4, pp. 503–528, 1986.
  24. T. N. Petruzziello-Pellegrini and P. A. Marsden, “Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics,” Current Opinion in Nephrology and Hypertension, vol. 21, no. 4, pp. 433–440, 2012.
  25. K. Poolpol, B. Gadner, S. Neururer et al., “Do complement factor H 402Y and C7 M allotypes predispose to (typical) haemolytic uraemic syndrome?” International Journal of Immunogenetics, vol. 38, no. 5, pp. 383–387, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Campbell and I. J. Carré, “Fatal haemolytic uraemic syndrome and idiopathic hyperlipaemia in monozygotic twins,” Archives of Disease in Childhood, vol. 40, no. 214, pp. 654–658, 1965. View at Scopus
  27. C. J. F. Boon, N. C. van de Kar, B. J. Klevering et al., “The spectrum of phenotypes caused by variants in the CFH gene,” Molecular Immunology, vol. 46, no. 8-9, pp. 1573–1594, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Warwicker, T. H. J. Goodship, R. L. Donne et al., “Genetic studies into inherited and sporadic hemolytic uremic syndrome,” Kidney International, vol. 53, no. 4, pp. 836–844, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Martinez-Barricarte, G. Pianetti, R. Gautard et al., “The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome,” Journal of the American Society of Nephrology, vol. 19, no. 3, pp. 639–646, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Caprioli, F. Castelletti, S. Bucchioni et al., “Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease,” Human Molecular Genetics, vol. 12, no. 24, pp. 3385–3395, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Ying, Y. Katz, M. Schlesinger et al., “Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome,” American Journal of Human Genetics, vol. 65, no. 6, pp. 1538–1546, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Hakobyan, A. Tortajada, C. L. Harris, S. R. De Córdoba, and B. P. Morgan, “Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome,” Kidney International, vol. 78, no. 8, pp. 782–788, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Sullivan, Z. Erlic, M. M. Hoffmann et al., “Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome,” Annals of Human Genetics, vol. 74, no. 1, pp. 17–26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Habibi, I. Sfar, W. Ben Alaya, et al., “Atypical hemolytic uremic syndrome and mutation analysis of factor H gene in two Tunisian families,” International Journal of Nephrology and Renovascular Disease, vol. 3, pp. 85–92, 2010.
  35. L. T. Roumenina, C. Loirat, M. A. Dragon-Durey, L. Halbwachs-Mecarelli, C. Sautes-Fridman, and V. Frémeaux-Bacchi, “Alternative complement pathway assessment in patients with atypical HUS,” Journal of Immunological Methods, vol. 365, no. 1-2, pp. 8–26, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Sofat, J. P. Casas, A. R. Webster, et al., “Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype,” International Journal of Epidemiology, vol. 41, no. 1, pp. 250–262, 2012.
  37. A. Servais, L. H. Noël, L. T. Roumenina, et al., “Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies,” Kidney International, vol. 82, no. 4, pp. 454–464, 2012.
  38. N. J. Francis, B. McNicholas, A. Awan, et al., “A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome,” Blood, vol. 119, no. 2, pp. 591–601, 2012.
  39. J. Cardone, G. Le Friec, and C. Kemper, “CD46 in innate and adaptive immunity: an update,” Clinical and Experimental Immunology, vol. 164, no. 3, pp. 301–311, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Richards, E. J. Kemp, M. K. Liszewski et al., “Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 22, pp. 12966–12971, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Noris, S. Brioschi, J. Caprioli et al., “Familial haemolytic uraemic syndrome and an MCP mutation,” The Lancet, vol. 362, no. 9395, pp. 1542–1547, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. V. Frémeaux-Bacchi, E. A. Moulton, D. Kavanagh et al., “Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome,” Journal of the American Society of Nephrology, vol. 17, no. 7, pp. 2017–2025, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Esparza-Gordillo, E. G. D. Jorge, C. A. Garrido et al., “Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree,” Molecular Immunology, vol. 43, no. 11, pp. 1769–1775, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Provaznikova, S. Rittich, M. Malina et al., “Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP,” Pediatric Nephrology, vol. 27, no. 1, pp. 73–81, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. M. K. Liszewski, C. Kemper, J. D. Price, and J. P. Atkinson, “Emerging roles and new functions of CD46,” Springer Seminars in Immunopathology, vol. 27, no. 3, pp. 345–358, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Richards, M. Kathryn Liszewski, D. Kavanagh et al., “Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome,” Molecular Immunology, vol. 44, no. 1–3, pp. 111–122, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. R. E. Saunders, C. Abarrategui-Garrido, V. Frémeaux-Bacchi et al., “The interactive factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and factor I mutations with structural models,” Human Mutation, vol. 28, no. 3, pp. 222–234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Esparza-Gordillo, E. Goicoechea de Jorge, A. Buil et al., “Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32,” Human Molecular Genetics, vol. 14, no. 5, pp. 703–712, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Ermini, T. H. Goodship, L. Strain, et al., “Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS,” Molecular Immunology, vol. 49, no. 4, pp. 640–648, 2012.
  50. V. Frémeaux-Bacchi, E. C. Miller, M. K. Liszewski et al., “Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome,” Blood, vol. 112, no. 13, pp. 4948–4952, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. D. K. Lhotta, A. R. Janecke, J. Scheiring et al., “A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 8, pp. 1356–1362, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. L. Sartz, A. I. Olin, A. C. Kristoffersson, et al., “A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome,” Journal of Immunology, vol. 188, no. 4, pp. 2030–2037, 2012.
  53. E. Goicoechea de Jorge, C. L. Harris, J. Esparza-Gordillo et al., “Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 1, pp. 240–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. C. A. Alper, F. S. Rosen, and P. J. Lachmann, “Inactivator of the third component of complement as an inhibitor in the properdin pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 69, no. 10, pp. 2910–2913, 1972. View at Scopus
  55. S. C. Nilsson, R. B. Sim, S. M. Lea, et al., “Complement factor I in health and disease,” Molecular Immunology, vol. 48, no. 14, pp. 1611–1620, 2011.
  56. M. Sullivan, L. A. Rybicki, A. Winter, et al., “Age-related penetrance of hereditary atypical hemolytic uremic syndrome,” Annals of Human Genetics, vol. 75, no. 6, pp. 639–647, 2011.
  57. D. Westra, J. F. Wetzels, E. B. Volokhina, et al., “A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome,” The Netherlands Journal of Medicine, vol. 70, no. 3, pp. 121–129, 2012.
  58. C. Loirat and V. Frémeaux-Bacchi, “Atypical hemolytic uremic syndrome,” Orphanet Journal of Rare Diseases, vol. 6, p. 60, 2011.
  59. J. Zuber, M. Le Quintrec, R. Sberro-Soussan, C. Loirat, V. Frémeaux-Bacchi, and C. Legendre, “New insights into postrenal transplant hemolytic uremic syndrome,” Nature Reviews Nephrology, vol. 7, no. 1, pp. 23–35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. J. M. Saland, P. Ruggenenti, G. Remuzzi, and Consensus Study Group, “Liver-kidney transplantation to cure atypical hemolytic uremic syndrome,” Journal of the American Society of Nephrology, vol. 20, no. 5, pp. 940–949, 2009.